Drug development and patent law
Nusbaum, N.J.
New York State Journal of Medicine 92(3): 86-87
1992
ISSN/ISBN: 0028-7628 PMID: 1557205 Document Number: 397704
Document emailed within 1 workday
Related Documents
Halliburton, M. 2009: Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime Global Public Health 4(6): 515-527Banci, F. 1970: Latest status of the drug patent law Bollettino Chimico Farmaceutico 109(12): 699-701
Whitehouse, P.J.; Sciulli, C.G.; Mason, R.M. 1997: Dementia drug development: use of information systems to harmonize global drug development Psychopharmacology Bulletin 33(1): 129-133
Watson, R. 2010: European Commission targets drug firms over illegal patent protection Bmj 340: C268
Pavento, L.C.; Greene, J.L.; McDonald, J.K. 2003: International patent protection for HIV-related therapies: patent attorney's perspective Emory international law review 17(2): 919-931
Nesytova, N.Iu.; Paleva, N.S.; Il'ina, E.V.; Shenk, P.; Bendas, F.; Nun, P. 1990: Trends in the development of research in the field of liposomes (review of patent literature) Vestnik Akademii Meditsinskikh Nauk SSSR 1990(6): 8-19
Faunce, T. 2015: Australian Competition and Consumer Commission V Pfizer: Evergreening and Market Power as a Blockbuster Drug Goes off Patent Journal of Law and Medicine 22(4): 771-787
Kelloff, G.J.; Crowell, J.A.; Boone, C.W.; Steele, V.E.; Lubet, R.A.; Greenwald, P.; Alberts, D.S.; Covey, J.M.; Doody, L.A.; Knapp, G.G. 1994: Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute Journal of Cellular Biochemistry. Supplement 20: 55-62
Schiff, J. 2016: Patently perturbed. Trans-Pacific Partnership trade deal raises fears about drug patent periods, higher costs Modern Healthcare 46(23): 36-38
Olsson, H. 1999: Commercialization of genes--breast cancer gene patent is a pilot case. Sweden must play a part in the development Lakartidningen 96(37): 3920-3923
Sergeev, V.M.; Demidov, N.A. 1973: Perspectives of the development of innovations, inventions and patent-license work at the scientific-research institutes and universities of the Department of Public Health of the RSFSR Zdravookhranenie Rossiiskoi Federatsii 17(4): 3-7
Leape, L.L.; Ching, N.; Holder, T.M. 1970: Lobar emphysema and patent ductus arteriosus. Development of emphysema while under observation Pediatrics 46(1): 97-101
Kutter, E.; Austel, V. 1981: Application of the theory of sets to drug design. Development of a new cardiotonic drug AR-L 115 BS Arzneimittel-Forschung 31(1a): 135-141
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Thomas, J.W. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Liability issues Journal of the American Veterinary Medical Association 207(7): 899-900; Discussion: 902-904
Askaa, B.; Horwitz, H.; Wøien, V.A.é; Høgberg, L.C.G.; Jürgens, G. 2014: The development from drug to designer drug Ugeskrift for Laeger 176(42)
Apley, M.D. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots Journal of the American Veterinary Medical Association 207(7): 901
Stack 1996: Local Drug Delivery: the Development of a Drug Delivery Stent Journal of Invasive Cardiology 8(8): 396-397
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Wagner, M. 1993: 'Renaissance' seen in drug development Modern Healthcare 23(6): 31